An Expert View from Róbert Wessman, founder and chairman of Icelandic biosimilars company Alvotech (Nasdaq: ALVO) and investment fund Aztiq.
The purpose of an appropriately balanced intellectual property (IP) system is to incentivize innovation and increase economic growth. Unfortunately, some pharma companies spend significant resources on manipulating the IP enforcement system to improperly extend expiring monopolies. They exploit unintended or unforeseen ambiguities in the law to crush competition rather than to protect innovation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze